

Molecular Therapeutics of Cancer Research Conference -- 2019

Sponsored by the Cancer Molecular Therapeutics Research Association

Granlibakken Tahoe Resort and Conference Center

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

All scientific sessions will be in the Mountain Room

Breaks, Poster sessions with refreshments will be in the Mountain Deck

The opening reception Sunday evening will be at Garden Deck

The farewell reception will be at Granhall

****Lodging will be at the Granlibakken Tahoe Resort ****

Meals will be at the Granhall (breakfast) and the Garden Deck (dinner)

SUNDAY – JULY 21

- | | |
|----------------|--|
| 4:00 pm | Arrival and check-in |
| 6:00 – 7:00 pm | <i>Dinner</i> |
| 7:30 – 7:45 pm | Welcome / Introductory Comments
Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX,
President CMTRA |
| 7:45 – 9:45 pm | KEYNOTE SPEAKER(s)
Levi Garraway, Lilly
“The science of oncology therapeutic development”
Ray Deshaies, Amgen
“Induced proximity: the future of drugs?” |
| 10:00 pm – | <i>Opening reception</i> |

MONDAY – JULY 22

- | | |
|-----------------|---|
| 7:30 – 8:15 am | <i>Breakfast</i> |
| 8:30 – 12:00 pm | MORNING SESSION: Protein Homeostasis
Discussion Leader: James Winkler and Ray Deshaies |
| 8:30 – 8:45 am | Introduction |
| 8:45 – 9:15 am | Craig Crews, Departments of MCDB; Chemistry; Pharmacology, Yale University
“PROTAC-mediated Protein Degradation: A New Therapeutic Modality” |
| 9:15 – 9:40 am | Discussion |

9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Danette Daniels, Group Leader, Promega Corporation “Interrogating cellular mechanisms of targeted degradation compounds”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Deepak Nijhawan, U Texas Southwestern "Using chemistry to find new cancer targets"
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	OPEN NETWORKING AFTERNOON
5:00 – 6:30 pm	Poster Session and Social
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: Immuno-Oncology (I/O)
7:30 – 7:45 pm	Discussion Leader: Upendra Marathi, 7 Hills Pharma Introduction
7:45 – 8:15 pm	Kathleen Mahoney, Beth Israel Deaconess Medical Center, Boston “Prognostic and Predictive Markers for Immunotherapy and Combination Therapy”
8:15 – 8:45 pm	Discussion
8:45 – 9:15 pm	TBA
9:15 – 9:45 pm	Discussion
9:45 pm –	<i>Social</i>

TUESDAY JULY 23

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: Targeting RAS Discussion Leader: Frank McCormick, UCSF
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Rusty Lipford, Amgen “Pre-Clinical Development of AMG 510: The First Inhibitor of KRASG12C in Clinical Testing”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Coffee Break</i>

10:00 – 10:30 am	Dr Anna Maciag (Frederick National Lab) "Blocking C-terminal processing of KRAS4b via a direct covalent attack on the CaaX-box cysteine"
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Martin McMahon (Huntsman) "Rationale-targeting of therapeutic vulnerabilities in RAS-driven cancers"
11:30 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	OPEN NETWORKING AFTERNOON
5:00 – 6:30 pm	Poster Session and Social
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: Attacking Minimal Residual Disease Discussion Leader: Peter Houghton
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	Charles Sherr, MD St. Jude Children's Research Hospital "Rational Application of CDK4/6-Inhibitory Drugs"
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	Trever Bivona, UCSF "Mechanisms of the evolution of residual disease during targeted cancer therapy"
9:15 – 9:40 pm	Discussion
9:40 pm –	<i>Social</i>

WEDNESDAY JULY 24

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: Head & Neck Cancer Discussion Leader: Jennifer Grandis UCSF "Introduction. The Challenges and Opportunities for the Treatment of Head and Neck Cancer"
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Xiao-jing Wang, PhD University of Colorado "Therapeutic viability of targeting TGFbeta in Head & Neck Cancer"

9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Dan Johnson, PhD, UCSF "NSAID Therapy for PIK3CA-altered Head and Neck Cancer"
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	J. Silvio Gutkind, PhD, UCSD "Targeting oncogenic signaling circuitries and PD-1: Multimodal precision immunotherapy for head and neck cancer"
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	Lunch
2:00 – 3:00 pm	ORAL PRESENTATIONS – Four Selected Presenters from the Posters
3:00 – 5:30 pm	AFTERNOON SESSION: Liquid Biomarker Approaches
3:00 – 3:15 pm	Discussion Leader: Caroline Dive, University of Manchester Introduction
3:15 – 3:45 pm	Brian Crompton, Dana-Farber Cancer Institute "The Promise of Liquid Biopsies in Pediatric Solid Tumors"
3:45 -4:10 pm	Discussion
4:10 – 4:40 pm	Raghu Kalluri, MD Anderson "Strategies to Exploit the Biology of Exosomes for Diagnosis and Treatment of Cancer"
4:45 – 5:10 pm	Discussion
6:00 – 10:00 pm	<i>Farewell Reception</i>

THURSDAY JULY 25

11:00 am CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting is co-sponsored by the

This meeting would not be possible without the generous contributions from our many friends and colleagues: